Table 1. Optimization of the ex vivo IFN-γ ELISpot assay.
| Adjusted IFN-γ Spot Count (SFC/106 PBMC) | ||||||||
|---|---|---|---|---|---|---|---|---|
| OT infected | Controls | |||||||
| Well #1 | Well #2 | Mean | 95%CI | Well #1 | Well #2 | Mean | 95%CI | |
| PHA | 155 | 195 | 175 | (0–429) | 440 | 405 | 422.5 | (200–645) |
| Media | 0 | 0 | 0 | (0–0) | 10 | 0 | 5 | (0–69) |
| OT 1.41 μg | 805 | 990 | 897.5 | (0–207) | 0 | 5 | 2.5 | (0–34) |
| OT 0.705 μg | 740 | 740 | 740 | (740–740) | 10 | 0 | 5 | (0–69) |
| OT 0.141 μg | 655 | 565 | 610 | (38–1182) | 15 | 5 | 10 | (0–34) |
Note: Spot counts are expressed as spot forming cells per million peripheral blood mononuclear cells (SFC/106 PBMC).